Moonen Marie, Oury Cécile, Lancellotti Patrizio
GIGA Cardiovascular Sciences, Departments of Cardiology, Cardio-Oncology Clinic, CHU Sart Tilman, University of Liège Hospital, 4000, Liège, Belgium.
Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy.
Curr Oncol Rep. 2017 Aug 8;19(10):63. doi: 10.1007/s11912-017-0622-5.
Contemporary cancer management has increased the overall number of cancer survivors, but cardiotoxicity remains a subject of concern, which is a major cause of noncancer mortality among survivors. Among the potential cardiovascular complications, left ventricular (LV) systolic dysfunction is a poor prognostic factor. The importance of its early detection is based on the principle that the likelihood of response to heart failure (HF) treatment is temporally related to the initiation of HF treatment. For these reasons, cardiac monitoring is commonly applied in general practice, based on serial measurements of LV ejection fraction (LVEF); transthoracic echocardiography (TTE) is generally used. However, the LVEF, as a diagnostic and predictive parameter, has significant limitations, which calls for more effective multimodality imaging strategies. This approach requires further study, but there is increasing available data in the literature, encouraging the combination of multimodality imaging parameters and techniques for early cancer therapeutic-related cardiac dysfunction (CTRCD) detection.
当代癌症管理增加了癌症幸存者的总数，但心脏毒性仍然是一个令人担忧的问题，它是幸存者中非癌症死亡的主要原因。在潜在的心血管并发症中，左心室（LV）收缩功能障碍是一个不良预后因素。早期检测其重要性的依据是，对心力衰竭（HF）治疗的反应可能性与HF治疗的启动在时间上相关。出于这些原因，基于左心室射血分数（LVEF）的系列测量，心脏监测在一般实践中普遍应用；通常使用经胸超声心动图（TTE）。然而，LVEF作为一种诊断和预测参数有显著局限性，这就需要更有效的多模态成像策略。这种方法需要进一步研究，但文献中的可用数据越来越多，鼓励将多模态成像参数和技术结合起来用于早期癌症治疗相关心脏功能障碍（CTRCD）的检测。
